| Added by | mollevi |
|---|---|
| Group name | EquipeAM |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: *Thoracic Oncology Unit, Arnaud de Villeneuve Hospital/CHRU Montpellier, Montpellier, France; daggerDepartment of Pneumology, University Hospital, KU Leuven, Leuven, Belgium; double daggerMedical Oncology, European Institute of Oncology, Milan, Italy; section signDivision of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah; paragraph signDepartment of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany; ||Department of Respiratory Medicine, Ziekenhuis Oost Limburg, Genk and LCRP Oncology Cluster, University of Hasselt, Hasselt, Belgium; #Department of Medical Oncologie, ICO R. Gauducheau, St-Herblain, France; **Department of Oncology, University Hospital S. Maria della misericordia, Udine, Italy; daggerdaggerNottingham University Hospitals NHS Trust, Nottingham, United Kingdom; double daggerdouble daggerNorthwest Lung Centre, University Hospitals of South Manchester, Manchester, United Kingdom; section sign section signThoracic Oncology-Pneumology Service, Andre Renard Clinic, Herstal, Belgium; paragraph sign paragraph signClinic of Thoracic Surgery, Waldburg-Zeil Clinic, Wangen im Allgau, Germany; and || ||GSK Vaccines, Rixensart, Belgium. alt-title: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer number: 10 accession-num: 26309191 |
| Tags | _EndnoteXML import |
| Date Added | 2018/11/14 - 12:43:03 |
| Date Modified | 2018/11/14 - 12:43:03 |
| Parent item | Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer |
Institut de Recherche en Cancérologie de
